CEO updatefew minutes ago: on
Dear Shareholders and Friends:
In opening this CEO update, I acknowledge that shareholders and interested parties wish to have news about HeartCheckTM PEN sales, SMART Monitoring based revenue and the progress made with distribution agreements. I have stated that we have interest from North American and international distributors and this continues to hold true. We are now currently working with 22 different distribution groups, all of whom have ordered and paid for evaluation units of the HeartCheckTM devices with SMART Monitoring access rights.
There is an update to make on the distributor agreement to sell HeartCheckTM devices into the Gulf region with Waisco Medical and Scientific Solutions’. We have been in discussions with this company’s senior management regarding the length of time that has passed without sales. Waisco continues to confirm their obligations under the contract and have requested additional time to meet their performance milestones. Meanwhile, we are now working to sign additional (multi) distribution opportunities within the region.
Discussions are underway with organizations to set up pharmacy-based sales channels. Associated with this, we are expanding infrastructure to support our SMART Monitoring services overseas and this will include multi-language GEMS Home releases. We also will report on the use of the HeartCheckTM PEN, HeartCheckTM ECG handheld monitor and our patent pending SMART Monitoring technologies in clinical research studies – one such report is scheduled to be disclosed at the Canadian Cardiovascular Society meeting to be held in Montréal, Canada in the fall.
Each time an update is prepared it is challenging to make it comprehensive enough to address issues of interest such as capitalization of the Company, social media marketing, pharmacy-based distribution models, new device integration for Bluetooth connectivity to smart phones and development of call service models with the HeartCheckTM products and patent pending SMART Monitoring service. What I can tell you is that each of these aforementioned topics are actively being managed and we may well be able to report on each of them separately in press releases within the remaining 2013 calendar year.
In closing, I thank those shareholders and HeartCheckTM PEN customers who have been emailing and calling me with their support and continued interest in CardioComm Solutions and the HeartCheckTM PEN. Your personal experiences continue to demonstrate that we are on the right path in offering innovative solutions in personalized health management. In regards to inquiries about the company, we hear you. What I can say is the Company is doing well and we continue to look forward to making announcements which will demonstrate CardioComm Solutions’ unique position in the medical ECG management and consumer ECG monitoring markets. This is a company that will make a positive difference in many lives.
On behalf of the staff of CardioComm Solutions, we wish you all a safe and relaxing summer.
Sincerely,
Etienne Grima